Company Update: Merck & Co Inc (NYSE:MRK) – U.S. appeals court invalidates four Merck Cubicin patents

[Reuters] – Drugmaker Merck & Co Inc said the U.S. Court of Appeals for the Federal Circuit invalidated four patents related to the antibiotic, Cubicin, that expire in 2019 and 2020. The drugmaker . . . → Read More: Company Update: Merck & Co Inc (NYSE:MRK) – U.S. appeals court invalidates four Merck Cubicin patents Similar Articles: Company Update: Merck & Co Inc (NYSE:MRK) – Merck’s Pembrolizumab Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 Company Update: Merck & Co Inc (NYSE:MRK) – Liaison Technologies and Merck Cut the Ribbon for a Collaborative Innovation Center on NC State’s Centennial Campus Market Update: Merck & Co Inc (NYSE:MRK) – Indian court bars Glenmark from selling Merck drug copies